Literature DB >> 31624944

Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study.

Eliza R C Hagens1, Hannah T Künzli2, Anne-Sophie van Rijswijk1, Sybren L Meijer3, R Clinton D Mijnals3, Bas L A M Weusten2, E Debby Geijsen4, Hanneke W M van Laarhoven5, Mark I van Berge Henegouwen1, Suzanne S Gisbertz6.   

Abstract

BACKGROUND: The distribution of lymph node metastases in esophageal adenocarcinoma following neoadjuvant chemoradiation (nCRTx) is unclear, but may have consequences for radiotherapy and surgery. The aim of this study was to define the distribution of lymph node metastases and relation to the radiation field in patients following nCRTx and esophagectomy.
METHODS: Between April 2014 and August 2015 esophageal adenocarcinoma patients undergoing transthoracic esophagectomy with 2-field lymphadenectomy following nCRTx were included in this prospective observational study. Lymph node stations according to AJCC 7 were separately investigated. The location of lymph node metastases in relation to the radiation field was determined. The primary endpoint was the distribution of lymph node metastases and relation to the radiation field, the secondary endpoints were high-risk stations and risk factors for lymph node metastases and relation to survival.
RESULTS: Fifty consecutive patients were included. Lymph node metastases were found in 60% of patients and most frequently observed in paraesophageal (28%), left gastric artery (24%), and celiac trunk (18%) stations. Fifty-two percent had lymph node metastases within the radiation field. The incidence of lymph node metastases correlated significantly with ypT-stage (p = 0.002), cT-stage (p = 0.005), lymph angioinvasion (p = 0.004), and Mandard (p = 0.002). The number of lymph node metastases was associated with survival in univariable analysis (HR 1.12, 95% CI 1.068-1.173, p < 0.001).
CONCLUSIONS: Esophageal adenocarcinoma frequently metastasizes to both the mediastinal and abdominal lymph node stations. In this study, more than half of the patients had lymph node metastases within the radiation field. nCRTx is therefore not a reason to minimize lymphadenectomy in patients with esophageal adenocarcinoma.

Entities:  

Keywords:  Esophageal adenocarcinoma; Lymph node metastases; Lymphadenectomy; Neoadjuvant therapy; Survival

Mesh:

Year:  2019        PMID: 31624944     DOI: 10.1007/s00464-019-07205-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  5 in total

Review 1.  Today's Mistakes and Tomorrow's Wisdom in the Surgical Treatment of Barrett's Adenocarcinoma.

Authors:  Giovanni Maria Garbarino; Mark Ivo van Berge Henegouwen; Suzanne Sarah Gisbertz; Wietse Jelle Eshuis
Journal:  Visc Med       Date:  2022-05-24

2.  Contrast-Enhanced Radiologic Evaluation of Gastric Conduit Emptying After Esophagectomy.

Authors:  Minke L Feenstra; Lily Alkemade; Janneke E van den Bergh; Suzanne S Gisbertz; Freek Daams; Mark I van Berge Henegouwen; Wietse J Eshuis
Journal:  Ann Surg Oncol       Date:  2022-10-10       Impact factor: 4.339

3.  Transhiatal esophagectomy as a treatment for locally advanced adenocarcinoma of the gastroesophageal junction: postoperative and oncologic results of a single-center cohort THE for locally advanced GEJC.

Authors:  Hélène Meillat; Vincent Niziers; Christophe Zemmour; Jacques Ewald; Jean-Philippe Ratone; Slimane Dermeche; Jérôme Guiramand
Journal:  World J Surg Oncol       Date:  2022-03-06       Impact factor: 3.253

4.  A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma.

Authors:  Smita Sihag; Tamar Nobel; Meier Hsu; Kay See Tan; Rebecca Carr; Yelena Y Janjigian; Laura H Tang; Abraham J Wu; Matthew J Bott; James M Isbell; Manjit S Bains; David R Jones; Daniela Molena
Journal:  Ann Surg       Date:  2020-11-17       Impact factor: 13.787

5.  Optimal Perioperative Pain Management in Esophageal Surgery: An Evaluation of Paravertebral Analgesia.

Authors:  Minke L Feenstra; Werner Ten Hoope; Jeroen Hermanides; Suzanne S Gisbertz; Markus W Hollmann; Mark I van Berge Henegouwen; Wietse J Eshuis
Journal:  Ann Surg Oncol       Date:  2021-05-28       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.